New York GDOL and Cancer Moonshot Summit: A Winning Combination
The LRG 2016 GIST Days of Learning Tour (GDOL) made a stop in New York City on June 29th. A GIST Day of Learning is a free, one-day program that provides both education and [...]
Fundación GIST Chile GIST Awareness Day Video
On the GIST Awareness Day, Fundación GIST Chile wants to be the voice of all people who require that Health Systems cover the treatments that we need.
GIST Day of Learning Portland 2016 Full Video
A GIST Day of Learning (GDOL) was held on March 30, 2016 at The Center for Health and Healing, OHSU Knight Cancer Institute, Portland Oregon. GDOL’s are smaller group events held throughout the [...]
LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions
Loxo Oncology announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]
Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
Thoughts on the Cancer Moonshot Summit
On July 29, 2016 I traveled to Howard University in Washington, DC to be a participant in Vice President Joe Biden’s Cancer Moonshot Summit. This invitation-only event was designed to bring together individuals and [...]
Ignyta Announces Results for Potential New Cancer Treatment
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]
14th NIH Pediatric and Wildtype GIST Clinic Convenes
If you have a mutation of any of the SDH subunits (a,b,c, or d), the next important question to ask is whether or not it is a germline mutation. (So far, data has indicated that 80% of SDH-deficient tumors are germline). The term "germline" means that the mutation is present in every cell of your body. Germline mutations are hereditary, and can be passed on to your children. For this reason, genetic testing and counseling could be informative for parents, siblings and other family members. If a family member tests positive for the mutation, this does not mean that they will get GIST.
NIH Pediatric and Wildtype GIST Clinic
The 14th Pediatric and Wildtype GIST Clinic was held at the National Institute of Health (NIH) in Bethesda, Maryland on June 15-17, 2016. What follows is a summary of the discussion held during the [...]
GIST Day of Learning Miami 2016 Q&A Testimonial
Q & A Panel with the speakers of the 2016 Miami GDOL. GDOLs are smaller group events held throughout the year in cities nationwide. These events focus on helping patients and caregivers learn more about this [...]